An Open Label, Single Center, Adaptive Phase I Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist)
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Ronacaleret (Primary) ; Plerixafor
- Indications Osteoporosis; Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 11 Jul 2013 New trial record